Tiziana Life Sciences (NASDAQ:TLSA) has been given a $20.00 price objective by equities research analysts at Laidlaw in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a “buy” rating on the stock. Laidlaw’s price target points to a potential upside of 173.97% from the stock’s current price.

TLSA traded up $0.10 during midday trading on Tuesday, reaching $7.30. The company had a trading volume of 12,140 shares, compared to its average volume of 3,837. Tiziana Life Sciences has a 12-month low of $5.00 and a 12-month high of $12.17. The business has a 50-day moving average price of $6.88 and a two-hundred day moving average price of $7.05.

About Tiziana Life Sciences

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.

Featured Article: S&P 500 Index

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.